Elevated levels of methylmalonate and homocysteine in Parkinson's disease, progressive supranuclear palsy and amyotrophic lateral sclerosis

Dementia and Geriatric Cognitive Disorders

Volumn 29, Issue 6, 2010, Pages 553-559

  Levin, Johannes ^a   Bötzel, Kai ^a   Giese, Armin ^b   Vogeser, Michael ^a   Lorenzl, Stefan ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Amyotrophic lateral sclerosis; Homocysteine; Levodopa; Methylmalonate; Parkinson's disease; Progressive supranuclear palsy; Vitamin

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; METHYLMALONIC ACID;

ADULT; AGED; AMINO ACID BLOOD LEVEL; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CYANOCOBALAMIN DEFICIENCY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; URINALYSIS;

AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; CASE-CONTROL STUDIES; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; MALE; MATCHED-PAIR ANALYSIS; METHYLMALONIC ACID; MIDDLE AGED; PARKINSON DISEASE; REFERENCE VALUES; SUPRANUCLEAR PALSY, PROGRESSIVE; VITAMIN B 12;

EID: 77954189158     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314841     Document Type: Article

References (40)

1. Tolosa E, Wenning G, Poewe W: The diagnosis of Parkinson's disease. Lancet Neurol 2006; 5: 75-86.
2. Houghton DJ, Litvan I: Unraveling progressive supranuclear palsy: from the bedside back to the bench. Parkinsonism Relat Disord 2007; 13(suppl 3):S341-S346.
3. Wolfson C, Kilborn S, Oskoui M, Genge A: Incidence and prevalence of amyotrophic lateral sclerosis in Canada: a systematic review of the literature. Neuroepidemiology 2009; 33: 79-88.
4. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM: Folate, vitamin B 12 , and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998; 55: 1449-1455.
5. Morris MS: Homocysteine and Alzheimer's disease. Lancet Neurol 2003; 2: 425-428.
6. O'Suilleabhain P, Diaz-Arrastia R: Levodopa elevates homocysteine: is this a problem? Arch Neurol 2004; 61: 633-634.
7. Allain P, Le BA, Cordillet E, Le QL, Bagheri H, Montastruc JL: Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicology 1995; 16: 527-529.
8. Yasui K, Nakaso K, Kowa H, Takeshima T, Nakashima K: Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. Acta Neurol Scand 2003; 108: 66-67.
9. Isobe C, Murata T, Sato C, Terayama Y: Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease. Life Sci 2005; 77: 1836-1843.
10. Lamberti P, Zoccolella S, Iliceto G, Armenise E, Fraddosio A, de Mari M, et al: Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Mov Disord 2005; 20: 69-72. (Pubitemid 40277507)
11. Postuma RB, Espay AJ, Zadikoff C, Suchowersky O, Martin WR, Lafontaine AL, et al: Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology 2006; 66: 1941-1943.
12. Valkovic P, Benetin J, Blazicek P, Valkovicova L, Gmitterova K, Kukumberg P: Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients. Parkinsonism Relat Disord 2005; 11: 253-256.
13. Blandini F, Fancellu R, Martignoni E, Mangiagalli A, Pacchetti C, Samuele A, et al: Plasma homocysteine and L -dopa metabolism in patients with Parkinson disease. Clin Chem 2001; 47: 1102-1104.
14. dos Santos EF, Busanello EN, Miglioranza A, Zanatta A, Barchak AG, Vargas CR, et al: Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease. Metab Brain Dis 2009; 24: 257-269.
15. Todorovic Z, Dzoljic E, Novakovic I, Mirkovic D, Stojanovic R, Nesic Z, et al: Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. J Neurol Sci 2006; 248: 56-61.
16. Valentino F, Bivona G, Butera D, Paladino P, Fazzari M, Piccoli T, et al: Elevated cerebrospinal fluid and plasma homocysteine levels in ALS. Eur J Neurol 2010; 17: 84-89.
17. Zoccolella S, Simone IL, Lamberti P, Samarelli V, Tortelli R, Serlenga L, et al: Elevated plasma homocysteine levels in patients with amyotrophic lateral sclerosis. Neurology 2008; 70: 222-225.
18. Obeid R, Schorr H, Eckert R, Herrmann W: Vitamin B 12 status in the elderly as judged by available biochemical markers. Clin Chem 2004; 50: 238-241.
19. Boxer AL, Kramer JH, Johnston K, Goldman J, Finley R, Miller BL: Executive dysfunction in hyperhomocystinemia responds to homocysteine- lowering treatment. Neurology 2005; 64: 1431-1434.
20. Sachdev PS, Valenzuela M, Wang XL, Looi JC, Brodaty H: Relationship between plasma homocysteine levels and brain atrophy in healthy elderly individuals. Neurology 2002; 58: 1539-1541.
21. Durga J, van Boxtel MP, Schouten EG, Kok FJ, Jolles J, Katan MB, et al: Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet 2007; 369: 208-216.
22. de Lau LM, Koudstaal PJ, van Meurs JB, Uitterlinden AG, Hofman A, Breteler MM: Methylenetetrahydrofolate reductase C677T genotype and PD. Ann Neurol 2005; 57: 927-930.
23. Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP: Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 2002; 80: 101-110.
24. Ho PI, Ashline D, Dhitavat S, Ortiz D, Collins SC, Shea TB, et al: Folate deprivation induces neurodegeneration: roles of oxidative stress and increased homocysteine. Neurobiol Dis 2003; 14: 32-42.
25. Sachdev PS: Homocysteine and brain atrophy. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 1152-1161.
26. Loscalzo J: Homocysteine and dementias. N Engl J Med 2002; 346: 466-468.
27. Narasimhan P, Sklar R, Murrell M, Swanson RA, Sharp FR: Methylmalonyl-CoA mutase induction by cerebral ischemia and neurotoxicity of the mitochondrial toxin methylmalonic acid. J Neurosci 1996; 16: 7336-7346.
28. Kruman II, Kumaravel TS, Lohani A, Pedersen WA, Cutler RG, Kruman Y, et al: Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci 2002; 22: 1752-1762.
29. Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN: Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 2009; 132: 156-171.
30. Hughes AJ, Daniel SE, Blankson S, Lees AJ: A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50: 140-148.
31. Vogeser M, Muller W, Lorenzl S: External quality assessment of urinary methylmalonic acid quantification - results of a pilot study. Clin Chem Lab Med 2007; 45: 695-696.
32. Matchar DB, Feussner JR, Millington DS, Wilkinson RH Jr, Watson DJ, Gale D: Isotope- dilution assay for urinary methylmalonic acid in the diagnosis of vitamin B 12 deficiency. A prospective clinical evaluation. Ann Intern Med 1987; 106: 707-710.
33. Lindgren A: Elevated serum methylmalonic acid. How much comes from cobalamin deficiency and how much comes from the kidneys? Scand J Clin Lab Invest 2002; 62: 15-19.
34. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz- Arrastia R: Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 2003; 60: 59-64.
35. Obeid R, Herrmann W: Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett 2006; 580: 2994-3005.
36. Sung JJ, Kim HJ, Choi-Kwon S, Lee J, Kim M, Lee KW: Homocysteine induces oxidative cytotoxicity in Cu,Zn-superoxide dismutase mutant motor neuronal cell. Neuroreport 2002; 13: 377-381.
37. Klee GG: Cobalamin and folate evaluation: measurement of methylmalonic acid and homocysteine vs vitamin B(12) and folate. Clin Chem 2000; 46: 1277-1283.
38. Schuck PF, Rosa RB, Pettenuzzo LF, Sitta A, Wannmacher CM, Wyse AT, et al: Inhibition of mitochondrial creatine kinase activity from rat cerebral cortex by methylmalonic acid. Neurochem Int 2004; 45: 661-667.
39. Obeid R, Schadt A, Dillmann U, Kostopoulos P, Fassbender K, Herrmann W: Methylation status and neurodegenerative markers in Parkinson disease. Clin Chem 2009; 55: 1852-1860.
40. Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA: Effect of L -dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 2003; 60: 1125-1129.